Patient Isolation Articles & Analysis
13 news found
Its HUB offers a consolidated view of all patients during the birthing process that helps improve acuity awareness. ...
The prospective, single-arm study is evaluating the safety and efficacy of the reSept™ ASD Occluder, the first occluder with a metal-free, bioresorbable frame, for the treatment of patients with clinically significant, isolated ASDs. Primary endpoints will be compared with established performance goals for previously FDA-approved transcatheter ASD ...
The prospective, single-arm study is evaluating the safety and efficacy of the reSept™ ASD Occluder, the first occluder with a metal-free, bioresorbable frame, for the treatment of patients with clinically significant, isolated ASDs. Primary endpoints will be compared with established performance goals for previously FDA-approved transcatheter ASD ...
Patients with Isolated Systolic Hypertension (ISH) treated with BackBeat CNT experienced clinically meaningful and statistically significant reductions of 7.4 mmHg in ambulatory systolic blood pressure and 9.4 mmHg in ambulatory Pulse Pressure at 6 months compared to controls. ...
The average age of the study population was 74 years, which is significantly older than patients generally enrolled in hypertension studies. There was also a higher prevalence of comorbid conditions in the study population and 81% of enrolled patients had isolated systolic hypertension (ISH), a more dangerous and difficult to treat form of ...
SAN CARLOS, California, July 28, 2021 — Galaxy Medical announced today that the ECLIPSE-AF 90-day remapping data, presented at the Stanford BioDesign New Arrhythmia Technologies retreat, demonstrated durable lesions and chronic pulmonary vein isolation (PVI). Also, the company has recently treated patients in the same study using CE-Marked catheters and ...
atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the US, will evaluate the safety and efficacy of the reSept ASD Occluder. ...
Clinically meaningful and statistically significant reduction of 16.6 mmHg in systolic blood pressure out to two years 88% of the treated patients had isolated systolic hypertension (ISH) 70.6% of all treated patients and 80% of treated ISH patients had their blood pressure under control at 24 months Orchestra ...
Initial clinical experience demonstrates longterm clinically effective closure of the ASDs treated with the company’s device.1 “I am excited to lead atHeart Medical and for the potential of our first product, the reSept ASD Occluder, for patients requiring ASD closure,” commented Laurent Grandidier, CEO of atHeart Medical. ...
Since the outbreak of COVID-19, other hospitals have adopted Velano’s PIVO device with COVID-19 suspected or infected patients to help: Enable RN staff, who are already in the patient’s room, to effectively and easily draw high quality lab samples – without requiring additional practitioners to enter COVID-19 rooms; Enforce social distancing ...
But in the case of the recent Coronavirus (COVID-19) outbreak early detection and isolation of potentially infectious patients is essential to prevent unnecessary exposures among patients, healthcare personnel, and visitors to a healthcare facility. According to CDC and WHO, besides other infection prevention protocols/precautions the following ...
Following a 30-day run-in period during which patients received only standard pacing along with anti-hypertensive medications, patients who met follow-up screening criteria for daytime ASBP, were randomized to BackBeat CNT or control groups. ...
The new Certification comes at a time when hospitals are grappling with the rising costs – both in terms of patient outcomes and funding – of healthcare associated infections and emerging pandemic risks. ...